Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non–Small-Cell Lung Cancer, a Phase II Study of the Hoosier Oncology Group: LUN04-77-Reference-Cited by-同舟云学术

Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non–Small-Cell Lung Cancer, a Phase II Study of the Hoosier Oncology Group: LUN04-77

Published:2013-05 Issue:3 Volume:14 Page:224-229
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Riggs Heather,Jalal Shadia I.,Baghdadi Tareq Al,Bhatia Sumeet,McClean John,Johnson Cynthia,Yu Menggang,Taber David,Harb Wael,Hanna Nasser

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference43 articles.

1. Prevalence of poor performance status in lung cancer patients: implications for research;Lilenbaum;J Thorac Oncol,2008

2. Should patient-rated performance status affect treatment decisions in advanced lung cancer?;Dajczman;J Thorac Oncol,2008

3. Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer;Schnadig;Cancer,2008

4. American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J Clin Oncol,2009

5. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel;Gridelli;Ann Oncol,2004

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion;Frontiers in Immunology;2021-12-13

2. International consensus on severe lung cancer—the first edition;Translational Lung Cancer Research;2021-06

3. Combination of Anti-angiogenics and Other Targeted Therapies;Tumor Angiogenesis;2019

4. VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story?;Annals of Translational Medicine;2018-12

5. Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non–Small-cell Lung Cancer on Progression-free and Overall Survival;Clinical Lung Cancer;2017-07